Our portfolio company, Emalex Biosciences, moves one step closer to a new drug application for an investigational therapeutic to reduce tics for people with Tourette syndrome.?
Today we announced positive topline data from our Phase 3 registrational study of an investigational therapeutic to reduce tics for people with Tourette syndrome. This is an outstanding milestone in our commitment to helping people with this chronic neurodevelopmental disorder. Read more: https://lnkd.in/g4VAvvPJ #TouretteSyndrome